
## Darren Finlay

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6567755/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	3-Dimensional Culture Systems for Anti-Cancer Compound Profiling and High-Throughput Screening Reveal Increases in EGFR Inhibitor-Mediated Cytotoxicity Compared to Monolayer Culture Systems. PLoS ONE, 2014, 9, e108283.	2.5	102
2	Novel Noncatalytic Role for Caspase-8 in Promoting Src-Mediated Adhesion and Erk Signaling in Neuroblastoma Cells. Cancer Research, 2007, 67, 11704-11711.	0.9	72
3	Connective tissue growth factor [CTGF]/CCN2 stimulates mesangial cell migration through integrated dissolution of focal adhesion complexes and activation of cell polarization. FASEB Journal, 2004, 18, 1541-1543.	0.5	71
4	Selective imaging of cathepsinÂL in breast cancer by fluorescent activity-based probes. Chemical Science, 2018, 9, 2113-2129.	7.4	64
5	FBXO44 promotes DNA replication-coupled repetitive element silencing in cancer cells. Cell, 2021, 184, 352-369.e23.	28.9	50
6	Small-Molecule IAP Antagonists Sensitize Cancer Cells to TRAIL-Induced Apoptosis: Roles of XIAP and cIAPs. Molecular Cancer Therapeutics, 2014, 13, 5-15.	4.1	48
7	Critical Role for Caspase-8 in Epidermal Growth Factor Signaling. Cancer Research, 2009, 69, 5023-5029.	0.9	47
8	Novel Role of Src in Priming Pyk2 Phosphorylation. PLoS ONE, 2016, 11, e0149231.	2.5	39
9	Functional Precision Medicine Identifies New Therapeutic Candidates for Medulloblastoma. Cancer Research, 2020, 80, 5393-5407.	0.9	38
10	Inducing death in tumor cells: roles of the inhibitor of apoptosis proteins. F1000Research, 2017, 6, 587.	1.6	35
11	Design, synthesis and evaluation of monovalent Smac mimetics that bind to the BIR2 domain of the anti-apoptotic protein XIAP. Bioorganic and Medicinal Chemistry Letters, 2011, 21, 4332-4336.	2.2	29
12	Differential Response of Glioma Stem Cells to Arsenic Trioxide Therapy Is Regulated by MNK1 and mRNA Translation. Molecular Cancer Research, 2018, 16, 32-46.	3.4	29
13	Expedient Synthesis of Highly Potent Antagonists of Inhibitor of Apoptosis Proteins (IAPs) with Unique Selectivity for ML-IAP. ACS Chemical Biology, 2013, 8, 725-732.	3.4	28
14	PTEN deficiency leads to proteasome addiction: a novel vulnerability in glioblastoma. Neuro-Oncology, 2021, 23, 1072-1086.	1.2	23
15	The ubiquitin ligase RNF5 determines acute myeloid leukemia growth and susceptibility to histone deacetylase inhibitors. Nature Communications, 2021, 12, 5397.	12.8	20
16	Novel HTS Strategy Identifies TRAIL-Sensitizing Compounds Acting Specifically Through the Caspase-8 Apoptotic Axis. PLoS ONE, 2010, 5, e13375.	2.5	18
17	MicroRNA-211 Modulates the DUSP6-ERK5 Signaling Axis to Promote BRAFV600E-Driven Melanoma Growth InÂVivo and BRAF/MEK Inhibitor Resistance. Journal of Investigative Dermatology, 2021, 141, 385-394.	0.7	17
18	Characterization of Potent SMAC Mimetics that Sensitize Cancer Cells to TNF Family-Induced Apoptosis. PLoS ONE, 2016, 11, e0161952.	2.5	17

DARREN FINLAY

#	Article	IF	CITATIONS
19	Analysis of variability in high throughput screening data: applications to melanoma cell lines and drug responses. Oncotarget, 2017, 8, 27786-27799.	1.8	9
20	Network Rewiring in Cancer: Applications to Melanoma Cell Lines and the Cancer Genome Atlas Patients. Frontiers in Genetics, 2018, 9, 228.	2.3	8
21	Cell adhesion suppresses autophagy via Src/FAK-mediated phosphorylation and inhibition of AMPK. Cellular Signalling, 2022, 89, 110170.	3.6	8
22	Discovery of novel furanylbenzamide inhibitors that target oncogenic tyrosine phosphatase SHP2 in leukemia cells. Journal of Biological Chemistry, 2022, 298, 101477.	3.4	6
23	SRC plays a specific role in the cross-talk between apoptosis and autophagy via phosphorylation of a novel regulatory site on AMPK. , 2022, 1, 38-41.		3
24	Nonlinear mixed effects dose response modeling in high throughput drug screens: application to melanoma cell line analysis. Oncotarget, 2018, 9, 5044-5057.	1.8	2
25	Optical Mapping Uncovers Multiple Novel Genomic Structural Variants in Patient Leukemias. Blood, 2020, 136, 33-34.	1.4	1
26	DDIS-05. PATIENT DERIVED NEUROSPHERE CULTURES IDENTIFY NOVEL CHEMOVULNERABILITIES IN GLIOBLASTOMA. Neuro-Oncology, 2018, 20, vi70-vi70.	1.2	0
27	DDIS-24. PROTEASOME INHIBITION IS A TARGETED THERAPY FOR PTEN-DEFICIENT GLIOBLASTOMAS. Neuro-Oncology, 2018, 20, vi74-vi74.	1.2	0
28	CADD-21. PROTEASOME INHIBITION IS A TARGETED THERAPY FOR PTEN-DEFICIENT GLIOBLASTOMAS. Neuro-Oncology, 2018, 20, vi280-vi280.	1.2	0
29	Drug Sensitivity Across Acute Myeloid Leukemia Subtypes Using an in Vitro Assay. Blood, 2016, 128, 5208-5208.	1.4	0
30	A Synthetic Lethal Approach to Eradicate AML Via Synergistic Activation of Pro-Apoptotic p53 By MDM2 and BET Inhibitors. Blood, 2020, 136, 14-14.	1.4	0
31	RNF5 Defines Acute Myeloid Leukemia Growth and Susceptibility to Histone Deacetylase Inhibitors. Blood, 2020, 136, 31-32.	1.4	0